[1]操利超,巴 颖,卢晓萍,等.基于TCGA和GEO数据库构建结肠癌预后模型[J].医学信息,2021,34(24):27-32.[doi:10.3969/j.issn.1006-1959.2021.24.006]
　CAO Li-chao,BA Ying,LU Xiao-ping,et al.Prognostic Model of Colon Cancer Based on TCGA and GEO Database[J].Medical Information,2021,34(24):27-32.[doi:10.3969/j.issn.1006-1959.2021.24.006]
点击复制

基于TCGA和GEO数据库构建结肠癌预后模型()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年24期
页码:
27-32
栏目:
论著
出版日期:
2021-12-15

文章信息/Info

Title:
Prognostic Model of Colon Cancer Based on TCGA and GEO Database
文章编号:
1006-1959（2021）24-0027-06
作者:
操利超; 巴 颖; 卢晓萍; 等
（深圳市核子基因科技有限公司，广东 深圳 518071）
Author(s):
CAO Li-chao; BA Ying; LU Xiao-ping; et al.
(Shenzhen Nucleus Gene Technology Co., Ltd.,Shenzhen 518071,Guangdong,China)
关键词:
结肠癌; 预后模型; 生物信息学; 病理分期; 复发
Keywords:
Colorectal cancer; Prognostic model; Bioinformatics; Pathological staging; Recurrence
分类号:
R714.24
DOI:
10.3969/j.issn.1006-1959.2021.24.006
文献标志码:
A
摘要:
目的 利用TCGA和GEO数据库中的基因表达数据和临床信息，挖掘结肠癌预后相关的基因，并构建和评估结肠癌预后模型。方法 从GEO数据库中下载结肠癌相关的基因表达矩阵，包括GSE44076、GSE28000和GSE39582，从TCGA数据库中下载结肠癌相关的mRNA表达数据矩阵和临床信息，通过NCBI数据库中在线分析软件GEO2R对三个GEO数据集进行差异基因分析，利用R包limma对TCGA数据集进行差异基因分析，获取共同的差异表达基因。通过单因子回归、LASSO回归和多因子回归分析构建结肠癌相关的预后模型，进一步结合临床特征构建列线图模型，综合评估预后模型的性能。结果 成功构建结肠癌相关的预后模型，构建的预后模型ROC曲线下面积在3年时为0.628，4年时为0.678，5年时为0.730；Wilcoxon检验显示，较高的风险评分与较高的T分期（P=0.049）、N分期（P=0.0015）、M分期（P=0.003）和病理分期（P=0.0019）相关；结合预后风险评分模型、年龄、性别和病理分期等级构建了列线图，模型的C-index从0.63增加至0.74。结论 本次构建的结肠癌预后模型在评估结肠癌患者复发风险分层、肿瘤分期等方面具有潜在意义。
Abstract:
Objective To explore the prognostic genes of colon cancer by using gene expression data and clinical information in TCGA and GEO databases, and to construct and evaluate the prognostic model of colon cancer.Methods The gene expression matrix related to colon cancer was downloaded from the GEO database, including GSE44076, GSE28000 and GSE39582. The mRNA expression data matrix and clinical information related to colon cancer were downloaded from the TCGA database. The differential gene analysis of the three GEO data sets was carried out through the online analysis software GEO2R in the NCBI database. The differential gene analysis of the TCGA data set was carried out R package limma to obtain the common differential expression genes. Prognostic models related to colon cancer were constructed through single factor regression, LASSO regression and multi-factor regression analysis, and the line chart model was further constructed combined with clinical characteristics to comprehensively evaluate the performance of the prognosis model.Results The colon cancer-related prognostic model was successfully constructed. The area under the ROC curve of the prognostic model was 0.628 at 3 years, 0.678 at 4 years and 0.730 at 5 years. Wilcoxon test showed that higher risk scores were correlated with higher T staging (P=0.049), N staging (P=0.0015), M staging (P=0.003) and pathological staging (P=0.0019). Combined with the prognostic risk score model, age, gender and pathological staging level, a line chart was constructed, and the C-index of the model increased from 0.63 to 0.74.Conclusion The constructed colon cancer prognosis model has potential significance in evaluating the recurrence risk stratification and tumor staging of colon cancer patients.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018(68):394-424.[2]Siegel RL,Miller KD,Goding Sauer A,et al.Colorectal cancer statistics,2020[J].CA Cancer J Clin,2020(70):145-164.[3]Wang JY,Wang CL,Wang XM,et al. Comprehensive analysis of microRNA/mRNA signature in colon adenocarcinoma[J].Eur Rev Med Pharmacol Sci,2017,21(9):2114-2129.[4]Müller MF, Ibrahim AE, Arends MJ. Molecular pathological classification of colorectal cancer[J].Virchows Arch,2016,469(2):125-134.[5]Rojas V,Hirshfield KM,Ganesan S,et al. Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment[J].Int J Mol Sci,2016,17(12):2113.[6]Conti I,Simioni C,Varano G,et al.MicroRNAs Patterns as Potential Tools for Diagnostic and Prognostic Follow-Up in Cancer Survivorship[J].Cells,2021,10(8):2069.[7]Chandra Gupta S,Nandan Tripathi Y.Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets[J].Int J Cancer,2017,140(9):1955-1967.[8]Chen K,Zhu P,Liao Y,et al.An Apoptotic Gene Signature for the Prognosis of Hepatocellular Carcinoma[J].Onco Targets Ther,2021(14):1589-1604.[9]Constancio V,Nunes SP,Henrique R,et al.DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types[J].Cells,2020,9(3):624.[10]Yang H,Liu H,Lin HC,et al.Association of a novel seven-gene expression signature with the disease prognosis in colon cancer patients[J].Aging (Albany NY),2019,11(19):8710-8727.[11]Chen X,Chen J,Feng Y,et al.Prognostic Value of SLC4A4 and its Correlation with Immune Infiltration in Colon Adenocarcinoma[J].Med Sci Monit,2020(26):e925016.[12]Schiffmann LM,Fritsch M,Gebauer F,et al.Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer[J].Br J Cancer,2019,120(1):69-78.[13]Toyoda T,Tsukamoto T,Yamamoto M,et al.Gene expression analysis of a Helicobacter pylori-infected and high-salt diet-treated mouse gastric tumor model: identification of CD177 as a novel prognostic factor in patients with gastric cancer[J].BMC Gastroenterol,2013(13):122.[14]Shangkuan WC,Lin HC,Chang YT,et al.Risk analysis of colorectal cancer incidence by gene expression analysis[J].Peer J,2017(5):e3003.[15]Chen Z,Yan X,Du GW,et al.Complement C7 (C7),a Potential Tumor Suppressor, Is an Immune-Related Prognostic Biomarker in Prostate Cancer (PC)[J].Front Oncol,2020(10):1532.[16]Ying L,Zhang F,Pan X,et al.Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis[J].Oncotarget,2016,7(52):86536-86546.[17]Wang S,Zhang C,Zhang Z,et al.Transcriptome analysis in primary colorectal cancer tissues from patients with and without liver metastases using next-generation sequencing[J].Cancer Med,2017,6(8):1976-1987.[18]Sisirak V,Sally B,D’Agati V,et al.Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity[J].Cell,2016,166(1):88-101.[19]Weisenburger T,von Neubeck B,Schneider A,et al.Epistatic Interactions Between Mutations of Deoxyribonuclease 1-Like 3 and the Inhibitory Fc Gamma Receptor IIB Result in Very Early and Massive Autoantibodies Against Double-Stranded DNA[J].Front Immunol,2018(9):1551.[20]Liu J,Yi J,Zhang Z,et al.Deoxyribonuclease 1-like 3 may be a potential prognostic biomarker associated with immune infiltration in colon cancer[J].Aging (Albany NY),2021,13(12):16513-16526.[21]Wu Z,Liu Z,Ge W,et al.Analysis of potential genes and pathways associated with the colorectal normal mucosa-adenoma-carcinoma sequence[J].Cancer Med,2018,7(6):2555-2566.[22]Li D,Zhao X,Xiao Y,et al.Intelectin 1 suppresses tumor progression and is associated with improved survival in gastric cancer[J].Oncotarget,2015,6(18):16168-16182.[23]Au-Yeung CL,Yeung TL,Achreja A,et al.ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment[J].Nat Commun,2020,11(1):3546.[24]Li D,Mei H,Pu J,et al.Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2[J].Mol Cancer,2015(14):47.[25]Kawashima K,Maeda K,Saigo C,et al.Adiponectin and Intelectin-1: Important Adipokine Players in Obesity-Related Colorectal Carcinogenesis[J].Int J Mol Sci,2017,18(4):866.[26]Klupp F,Neumann L,Kahlert C,et al.Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients[J].BMC Cancer,2016(16):494.[27]Zeng C,Chen Y.HTR1D, TIMP1, SERPINE1, MMP3 and CNR2 affect the survival of patients with colon adenocarcinoma[J].Oncol Lett,2019,18(3):2448-2454.

相似文献/References:

[1]苏周荣,杜东霖,魏正强.左半结肠癌伴梗阻一期切除吻合策略研究[J].医学信息,2018,31(10):51.[doi:10.3969/j.issn.1006-1959.2018.10.016]
　SU Zhou-rong,DU Dong-lin,WEI Zheng-qiang.Strategy of One-stage Resection and Anastomosis for Left Colon Cancer with Obstruction[J].Medical Information,2018,31(24):51.[doi:10.3969/j.issn.1006-1959.2018.10.016]
[2]石 磊,孙新增,李宝山,等.Ⅱ、Ⅲ期结肠癌患者辅助化疗XELOX方案、FOLFOX方案的临床疗效、不良反应及生活质量对比[J].医学信息,2018,31(13):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
　SHI Lei,SUN Xin-zeng,LI Bao-shan,et al.Clinical Efficacy,Adverse Reactions and Quality of Life of Adjuvant Chemotherapy XELOX and FOLFOX in Patients with Stage II and III Colon Cancer[J].Medical Information,2018,31(24):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
[3]王 超,范小华,张 力,等.下腔静脉畸形伴腹腔多脏器异位合并结肠癌1例[J].医学信息,2018,31(18):188.[doi:10.3969/j.issn.1006-1959.2018.18.062]
　WANG Chao,FAN Xiao-hua,ZHANG Li,et al.a Case of Inferior Vena Cava Malformation Associated with Multiple Abdominal Organ Ectopic Colon Cancer[J].Medical Information,2018,31(24):188.[doi:10.3969/j.issn.1006-1959.2018.18.062]
[4]黄富全.结合靶向药物综合治疗结肠癌肝及肝外转移术后7年1例报告[J].医学信息,2019,32(01):186.[doi:10.3969/j.issn.1006-1959.2019.01.061]
[5]葛菁茹,朱静雅,苏日新,等.以肺转移为首发表现的结肠癌预后分析[J].医学信息,2021,34(04):96.[doi:10.3969/j.issn.1006-1959.2021.04.025]
　GE Jing-ru,ZHU Jing-ya,SU Ri-xin,et al.Prognostic Analysis of Colon Cancer with Lung Metastasis as the First Manifestation[J].Medical Information,2021,34(24):96.[doi:10.3969/j.issn.1006-1959.2021.04.025]
[6]李 洋.北京市海淀区居民结肠癌防治知识知晓情况分析[J].医学信息,2021,34(08):141.[doi:10.3969/j.issn.1006-1959.2021.08.037]
　LI Yang.Analysis of Knowledge About Colon Cancer Prevention and Treatment Among Residents in Haidian District,Beijing[J].Medical Information,2021,34(24):141.[doi:10.3969/j.issn.1006-1959.2021.08.037]
[7]张祥鑫,董星星,耿 涛,等.基于与铁死亡相关基因的肺腺癌的新型预后模型构建[J].医学信息,2021,34(15):96.[doi:10.3969/j.issn.1006-1959.2021.15.025]
　ZHANG Xiang-xin,DONG Xing-xing,GENG Tao,et al.Construction of A Novel Prognostic Model of Lung Adenocarcinoma Based on Genes Related to Iron Death[J].Medical Information,2021,34(24):96.[doi:10.3969/j.issn.1006-1959.2021.15.025]
[8]查作霖,陈福军.MicroRNA-613调控ATOH1和FMNL2对结肠癌发生发展的影响[J].医学信息,2021,34(17):83.[doi:10.3969/j.issn.1006-1959.2021.17.021]
　ZHA Zuo-lin,CHEN Fu-jun.ATOH1 and FMNL2 on the Occurrence and Development of Colon Cancer[J].Medical Information,2021,34(24):83.[doi:10.3969/j.issn.1006-1959.2021.17.021]
[9]侯丁丁,赵 力.Ⅱ~Ⅲ期结肠癌术后辅助化疗方案[J].医学信息,2021,34(18):6.[doi:10.3969/j.issn.1006-1959.2021.18.002]
　HOU Ding-ding,ZHAO Li.Adjuvant Chemotherapy After Surgery for Stage Ⅱ~Ⅲ Colon Cancer[J].Medical Information,2021,34(24):6.[doi:10.3969/j.issn.1006-1959.2021.18.002]
[10]韩 猛,薛三宝,倪 丰.CT与MRI术前诊断结肠癌及评价术后复发的价值[J].医学信息,2021,34(21):175.[doi:10.3969/j.issn.1006-1959.2021.21.050]
　HAN Meng,XUE San-bao,NI Feng.Value of CT and MRI in Preoperative Diagnosis and Postoperative Recurrence of Colon Cancer[J].Medical Information,2021,34(24):175.[doi:10.3969/j.issn.1006-1959.2021.21.050]

更新日期/Last Update: 1900-01-01